IMMX insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Rachman Ilya M CEO, Chairman · Director · Immix Biopharma, Inc. | IMMX Immix Biopharma, Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 1143091.45 · SEC code covers open-market or private transactions | 2026-11-18 | 2026-11-20 | ≈ $10,000.00 1,408.45 shares/units | SEC 4 | Follow |
| Morris Gabriel S CFO, President · Director · Immix Biopharma, Inc. | IMMX Immix Biopharma, Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 292847 · SEC code covers open-market or private transactions | 2026-11-18 | 2026-11-20 | ≈ $10,011.08 1,418 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.